Tumor-Associated Transforming Growth Factor-β and Interleukin-10 Contribute to a Systemic Th2 Immune Phenotype in Pancreatic Carcinoma Patients
Open Access
- 1 August 1999
- journal article
- Published by Elsevier in The American Journal of Pathology
- Vol. 155 (2) , 537-547
- https://doi.org/10.1016/s0002-9440(10)65149-8
Abstract
No abstract availableKeywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (CA 25874)
- National Institutes of Health (CA 25874)
This publication has 68 references indexed in Scilit:
- Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.Journal of Clinical Investigation, 1993
- Factors, including transforming growth factor β, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cellsCancer Immunology, Immunotherapy, 1993
- Evidence That TGF-β Can Inhibit Human T-Lymphocyte Proliferation through Paracrine and Autocrine MechanismsCellular Immunology, 1993
- Interleukin-10Annual Review of Immunology, 1993
- A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.The Journal of Experimental Medicine, 1992
- Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells.The Journal of Experimental Medicine, 1992
- Pancreatic CarcinomaNew England Journal of Medicine, 1992
- Immunoregulatory effects of transforming growth factor-β in a prolonged period of cultureCellular Immunology, 1992
- The Transforming Growth Factor-beta FamilyAnnual Review of Cell Biology, 1990
- Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.The Journal of Experimental Medicine, 1986